Russia's R-Pharm secures approval of coronavir for outpatients

Russia's R-Pharm on Friday announced the approval of coronavir for outpatient treatment of mild to moderate COVID-19 coronavirus infection, it said in a statement.

MOSCOW, Sept 18 (Reuters) - Russia's R-Pharm on Friday announced the approval of coronavir for outpatient treatment of mild to moderate COVID-19 coronavirus infection, it said in a statement.

Coronavir, manufactured at R-Pharm's facility in Yaroslavl, will be available in pharmacies, the company added without elaborating.

(Writing by Katya Golubkova Editing by David Goodman )

((ekaterina.golubkova@thomsonreuters.com; +7 495 775 1242;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More